A phase IIa trial will investigate the efficacy, tolerability and pharmacokinetics of NB 001 (0.025%, 0.05% and 0.10%) when administered to patients with recurrent Herpes labialis.
Phase of Trial: Phase II
Latest Information Update: 07 May 2018
At a glance
- Drugs NB 001 (Primary)
- Indications Herpes labialis
- Focus Therapeutic Use
- Sponsors BlueWillow Biologics; NanoBio Corporation
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 08 Feb 2008 New trial record.